From Elsevier Business Intelligence
Including company and deal data plus articles from publications like IN VIVO, Start-Up, The RPM Report, and Medtech Insight.

Covidien Ltd.

www.covidien.com

Most Recent Related Deals

Covidien buys ev3 for $2.6bn in cash, 6/2010
Covidien divests its sleep therapy product line, 6/2010
Covidien to pay nearly $300mm for Somanetics, 6/2010
Covidien divests its specialty chemicals unit for $280mm, 5/2010
Covidien buys Orthofix's vascular business unit for $19mm, 3/2010
Covidien sells off product lines to embla and Caire, 9/2009
Covidien buys brain monitoring specialist Aspect for $212mm, 9/2009
Covidien pays $64mm for Power Medical Interventions, 7/2009
Aspect Medical gets US rights to the LiDCOrapid system, 7/2009
Ev3 adds to embolic product portfolio in Chestnut takeover, 6/2009

Most Recent Related Articles

Click an article to see a free preview (15 of 118).

Wound Care: Finding a Niche, The Pink Sheet DAILY 8/2010
Deals Update, The Pink Sheet DAILY 8/2010
Market & Industry Briefs, The Pink Sheet DAILY 8/2010
ASMBS Highlights New Developments in Bariatric Surgery, The Pink Sheet DAILY 8/2010
Women's Health: Building Interventional Gynecology, The Pink Sheet DAILY 8/2010
SurgiQuest Inc. , In Vivo 7/2010
The Future of Laparoscopy: Single Incision, NOTES and Robots , In Vivo 7/2010
Device VCs Find New Hope in Old Exit Path, Start-Up 7/2010
Market & Industry Briefs, The Pink Sheet DAILY 6/2010
Deals Update, The Pink Sheet DAILY 6/2010
Covidien Runs Familiar But Different Plays to Build Vascular Franchise, Start-Up 6/2010
Building Interventional Gynecology , In Vivo 6/2010
ev3 Rises Above IPO Device Class of 2005, In Vivo 6/2010
Market & Industry Briefs, The Pink Sheet DAILY 5/2010
Cappella: Can a New Twist On An Old Idea Solve the Bifurcation Challenge?, Start-Up 5/2010

See all 118 articles about this company

Copyright © 2009 Elsevier Inc. All rights reserved. Elsevier Business Intelligence, www.ElsevierBI.com.
Contact us at (800) 332-2181, +1 (908) 547-2159, or custcare@elsevier.com.